SBWire

Additive manufacturing or 3D printing allows manufacturers to produce objects using a digital file and wide array of printing materials. Automotive sector, besides aerospace & defense, healthcare, and manufacturing industries, exhibits growth in adoption of the technology. The technology is useful for applications ranging from printing car parts and accessories to manufacturing complex parts in less time as compared to traditional printers. The automotive companies adopt this technology at a remarkable rate in an effort to reduce the manufacturing costs, increase production rate, and lower the material wastage. The 3D printing technology has redefined the process of designing, developing, and manufacturing products in the automotive industry. The technology is being used for producing lighter and complex parts & accessories at reduced costs. Automotive part manufacturers are using 3D printers for effective usage of materials, reducing the lead time, and efficient logistics management. However, lack of skilled labors and high cost of 3D printers restrict the demand for 3D printers to some extent.

Pneumonia is indicated as a complex infection, which affects the lower part of the respiratory tract along with deposition of cough in the lungs. It may even occur as a consequence to an upper tract infection. Frequently, it occurs in people with weakened immunity, and in geriatric population and children. Biotechnological methods can be approached for testing of pneumonia such as enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR). The global pneumonia testing market was valued at $932 million in 2016, and is estimated to reach $1,738 million by 2023, registering a CAGR of 9.2% from 2017 to 2023.

Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. 3D printed drugs are developed by 3D printing technology to treat patients and children affected with dysphagia. These drugs are highly porous in nature and disintegrate rapidly, which eliminate the need to directly swallow the intact high-dose medicine.